By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Horizon Discovery today announced it has completed its acquisition of contract research organization Hypoxium and formed a wholly owned subsidiary called Horizon Discovery Services.

HDS will provide oncology translational research services, such as drug profiling, novel 2D and 3D phenotypic assays, tumor microenvironment studies, and responsive-patient prediction. The services include access to Horizon's 250-plus patient relevant human isogenic cancer cell models.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.